Waltham, Mass.-based NeuroMetrix said it is partnering with the Synovation medical group to carry out the study.
“We have seen both clinical data and positive reviews that suggest that Quell may be beneficial in reducing pain and improving the quality of life in people who suffer from fibromyalgia. This clinical evaluation will provide additional evidence for fibromyalgia patients and their healthcare providers who are considering Quell as a pain relief option,” NeuroMetrix prez & CEO Dr. Shai Gozani said in a prepared release.
“Clinical research on innovative therapies is an integral part of what we do. We are excited to test the Quell technology and potentially add it to our multidisciplinary approach to pain management,” Synovation Medical Group’s Dr. Kunal Gogna said in prepared remarks.
In June, NeuroMetrix said it is seeking CE Mark approval in the European Union for over-the-counter clearance for its Quell wearable chronic pain relief system. The company touted recent studies which indicate that 20-40% of the adult European population suffer fron chronic pain, with an annual financial cost exceeding $250 billion.
Earlier in June, NeuroMetrix said it closed a $21.3 million round of funding through the private placement of preferred stock and warrants to support its Quell device.